A critical review of what the course does well — and where it needs to go further to equip primary care clinicians with real-world, implementable guidance on ADHD and co-occurring conditions.
The PsychScene course provides a strong foundation in understanding ADHD — its presentations, diagnostic criteria, and pharmacological options. However, the gap between knowing what the evidence says and knowing how to apply it in a 15-minute GP consultation remains significant.
Perhaps the most clinically significant gap in the current course is the insufficient coverage of co-occurring autism and ADHD. Research consistently shows a 50–70% crossover between the two conditions — yet the course does not equip clinicians to identify, differentiate, or manage this presentation effectively.
Critically, co-diagnosis of autism and ADHD has only been permitted since 2013 (DSM-5). Many patients presenting today were assessed under older criteria that explicitly excluded dual diagnosis. This means a substantial cohort of adults may carry an incomplete or inaccurate diagnostic picture — and GPs are often the first point of contact.
The course currently includes questions about red flags for ADHD symptoms. These questions risk being clinically misleading when applied to individuals who are both autistic and have ADHD. Standard red flags — such as lateness, academic underperformance, or disorganisation — may be masked or compensated for in autistic individuals through rigid routines, hyperfocus, or significant effort.
Frequently late, disorganised, poor academic record, impulsive. These are the "textbook" red flags the course emphasises — and they apply to a subset of ADHD presentations.
Arrives two hours early, excels academically through intense effort, maintains rigid schedules — yet struggles profoundly with emotional regulation, sensory processing, and executive function in daily life.
Applying generalised red flag criteria alone means this individual is likely missed for both ADHD and autism — delaying appropriate support and potentially worsening outcomes.
Before arriving at a diagnosis of ADHD — and certainly before commencing treatment — it is essential to systematically rule out conditions that may mimic or co-exist with ADHD. The current course does not provide a clear, practice-ready framework for this process.
The clinical dictum is clear: address the most serious disorder first. Once comorbidities are stabilised, ADHD can then be appropriately treated — often with combined approaches. This sequencing is clinically important and must be made explicit in course content.
The course would benefit significantly from embedding structured clinical prompts that guide GPs through the diagnostic process. Using a referral-based case example, the following questions form a practical framework for adult ADHD assessment.
Identify presenting features consistent with ADHD — such as constant rushing, chronic sleep disturbance, difficulties sustaining attention, or longstanding executive dysfunction.
Systematically exclude mood disorders, anxiety disorders, psychotic presentations, thyroid dysfunction, sleep apnoea, and substance use — all of which can mimic or exacerbate ADHD symptoms.
Explore early school reports, behavioural patterns, family history (noting ADHD is highly heritable), and any prior assessments or diagnoses — including parental diagnoses.
Rating scales (e.g., ASRS), collateral history, structured clinical interview, and functional impairment assessment across multiple domains.
Determine whether the presentation is predominantly inattentive, predominantly hyperactive-impulsive, or combined — as subtype informs both communication and treatment planning.
The course covers stimulant pharmacology but does not adequately address what to do when first-line treatment fails. 10–30% of individuals with ADHD do not respond adequately to stimulant medications, or experience intolerable side effects that necessitate a change in approach. GPs need clear guidance on what comes next.
Consider switching between methylphenidate and amphetamine classes before concluding stimulant failure. Titration approach and timing of doses significantly affect response.
Common issues include appetite suppression, cardiovascular effects, sleep disruption, and anxiety. Dose adjustment, formulation change, or timing modification are first steps before abandoning the class.
Atomoxetine, guanfacine, and bupropion are evidence-based alternatives. Each has a distinct side effect and efficacy profile that the course should detail with titration guidance.
Cognitive Behavioural Therapy adapted for ADHD, coaching, psychoeducation, and lifestyle interventions (sleep, exercise, nutrition) are all evidence-based adjuncts that GPs should be able to recommend.
ADHD does not present uniformly across populations. The course touches on some demographic variation but does not go far enough in helping clinicians actively spot signs in under-recognised groups. Women, girls, and individuals from ethnic minority backgrounds are consistently diagnosed later — or not at all — due to masking, cultural bias, and assessment tools normed on white male populations.
Females with ADHD more often present with inattentive symptoms, internalising behaviours, anxiety, and emotional dysregulation. Hyperactivity may be less overt. Hormonal fluctuations across the menstrual cycle, perimenopause, and menopause can significantly worsen ADHD symptoms — an intersection the course rightly references but should expand considerably.
Black, Asian, and minority ethnic patients are less likely to receive an ADHD diagnosis due to clinician bias, cultural stoicism norms, and referral pathway disparities. The course should explicitly train clinicians to interrogate their assumptions and apply culturally sensitive screening approaches.
The course's reference to tracking menopause as part of ADHD management is a genuine strength — but it remains underdeveloped. Oestrogen has a direct modulatory effect on dopaminergic systems, meaning hormonal fluctuations during perimenopause and menopause can dramatically alter the efficacy of ADHD medications and unmask previously subclinical symptoms.
To make this content clinically actionable, the course should expand this section to include:
A structured tool clinicians can provide to patients for tracking ADHD symptoms across the menstrual cycle or menopause transition — correlating hormonal phases with functional impact.
A practical tracker for documenting stimulant dose, timing, efficacy, and side effects across hormonal phases — enabling data-driven titration adjustments at review appointments.
Explicit guidance on how HRT and hormonal contraceptives may interact with ADHD presentations and medication response — a clinically common scenario with very little accessible guidance.
GPs are generalists — not ADHD specialists. Yet the current course implicitly assumes a level of specialist knowledge that most GPs cannot reasonably be expected to hold. Several practical scenarios arise in clinical practice that the course does not adequately address.
ADHD is highly heritable. When a parent receives a diagnosis concurrent with their child, the GP must navigate dual management, family system dynamics, and the potential emotional impact of a late diagnosis. The course offers no guidance on this scenario.
Oppositional Defiant Disorder frequently co-occurs with ADHD. Should the GP simply inform the patient of the diagnosis? Refer? Provide psychoeducation? Without clear direction, clinicians are left to improvise — increasing the risk of inconsistent care.
The course should clearly delineate what is within a GP's scope to manage, what warrants referral to a psychiatrist or psychologist, and how to communicate these boundaries to patients without them feeling abandoned or dismissed.
The following additions would substantially elevate the PsychScene course from a strong educational resource to a genuinely practice-changing clinical tool for GPs managing ADHD across complex presentations.

One of the most impactful additions to the course would be a dedicated FAQ section for each module. Based on the content gaps identified, the following questions represent common points of uncertainty for GPs in clinical practice.
Use structured screening tools (e.g., AQ-10 alongside ASRS), take a detailed developmental history, and consider referral for formal neuropsychological assessment if both conditions are suspected. Do not rule out one on the basis of the other.
Initial assessment and screening can be completed across 2–3 extended consultations. Formal diagnosis — particularly for complex presentations — typically requires specialist input. GPs should focus on screening, history-taking, and initiating the referral pathway.
Symptoms present in two or more settings since childhood, functional impairment, and exclusion of alternative explanations. Validated rating scales and collateral history strengthen the clinical picture.
A structured feedback appointment — verbal explanation supported by written summary, psychoeducation materials, and a clear next-steps plan — is best practice. Avoid delivering significant diagnostic information incidentally at the end of a routine appointment.
The PsychScene course is a genuinely valuable resource — and with targeted expansion, it has the potential to meaningfully improve ADHD care at the primary care level. The core challenge is not content accuracy, but clinical translation: the distance between knowing what ADHD is and knowing how to act on that knowledge within the constraints of a real-world GP practice.
Addressing the gaps identified in this review — particularly around autism-ADHD comorbidity, differential diagnosis frameworks, intersectionality, non-stimulant pathways, and practical clinical tools — would transform the course into something GPs can carry directly into their consultations. That is the standard this course should aspire to.
Autism-ADHD crossover, ODD, mood and anxiety disorders — with explicit management sequencing.
FAQs, clinical decision frameworks, and step-by-step consultation guides for each major module.
Downloadable worksheets, medication trackers, symptom logs, and patient-facing psychoeducation resources.
Enhancing the PsychScene Course for GPs: Gaps, Opportunities & Clinical Action